Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 162.33M P/E - EPS this Y 4.00% Ern Qtrly Grth -
Income -68.88M Forward P/E -2.62 EPS next Y 23.10% 50D Avg Chg 1.00%
Sales 1.68M PEG 0.19 EPS past 5Y - 200D Avg Chg 9.00%
Dividend N/A Price/Book 1.58 EPS next 5Y -1.60% 52W High Chg -53.00%
Recommedations 3.00 Quick Ratio 4.65 Shares Outstanding 60.96M 52W Low Chg 76.00%
Insider Own 0.70% ROA -38.10% Shares Float 37.64M Beta 0.31
Inst Own 88.03% ROE -95.93% Shares Shorted/Prior 413.79K/223.03K Price 3.28
Gross Margin - Profit Margin - Avg. Volume 191,390 Target Price 0.95
Oper. Margin -4,421.81% Earnings Date Aug 6 Volume 58,772 Change 0.00%
About Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Lyra Therapeutics, Inc. News
05/07/24 Target upgraded, CVS downgraded: Wall Street's top analyst calls
05/06/24 Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
05/02/24 Lyra Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
04/30/24 Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
04/30/24 Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
04/26/24 Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/28/24 Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
03/26/24 Private equity firms who hold 39% of Lyra Therapeutics, Inc. (NASDAQ:LYRA) gained 6.8%, institutions profited as well
03/25/24 Lyra Therapeutics (LYRA) Is a Great Choice for 'Trend' Investors, Here's Why
03/23/24 Lyra Therapeutics Inc (LYRA) Posts Year-End Financial Results, Aligns with EPS Projections
03/22/24 Wall Street Analysts See a 101.81% Upside in Lyra Therapeutics (LYRA): Can the Stock Really Move This High?
03/21/24 Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
03/08/24 Here's Why Momentum in Lyra Therapeutics, Inc. (LYRA) Should Keep going
03/01/24 Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03/01/24 Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
02/29/24 5 Small Drug Stocks to Buy From a Rebounding Industry
02/26/24 Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?
02/21/24 Here's What Could Help Lyra Therapeutics, Inc. (LYRA) Maintain Its Recent Price Strength
02/07/24 Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?
01/17/24 What Makes Lyra Therapeutics, Inc. (LYRA) a Good Fit for 'Trend Investing'
LYRA Chatroom

User Image Alaaaaaaa999999 Posted - 1 hour ago

$LYRA 1 next week

User Image emilpepemil Posted - 4 hours ago

$LYRA ...first quarter of 2025... Cash, cash equivalents and short-term investments as of March 31, 2024 were $87.1 million, compared with $102.8 million at December 31, 2023. Based on our current business plan, we anticipate that our cash, cash equivalents and short-term investment balance is sufficient to fund our operating expenses and capital expenditures into the first quarter of 2025.

User Image BakuExchange Posted - 10 hours ago

$LYRA trades way under cash which is $1.43 per share

User Image Smallsmall Posted - 15 hours ago

$CRKN $AKAN $LYRA $NLSP let’s have more fun next week!

User Image phatmatt511 Posted - 18 hours ago

$LYRA

User Image ACInvestorBlog Posted - 19 hours ago

$LYRA another beaten down name that is showing some signs of reversal. Worth a look for next week.

User Image StockAuthority Posted - 21 hours ago

$LYRA has $2 price target recently, trades way under cash, gap to fill 10X higher, penny mania, what more do you want??? seriously $FFIE $GWAV

User Image ubernerd Posted - 23 hours ago

$LYRA im long LYRA at 39cents. good luck to all. 25k shares.

User Image RETAlerts Posted - 23 hours ago

The momentum is building for $LYRA at 0.394, now up 5% since our initial alert. Keep an eye on this one, as it could be primed for further gains. (15 minute delay)With a 10% gain since first being spotted on our scanner, $LYRA at 0.407 is starting to gather some serious momentum. Will this breakout continue? (15 minute delay)

User Image StockAuthority Posted - 23 hours ago

$LYRA added starter .39s here, lets see if it is my next $GGWAV 5 bagger, has gap to fill at $3.9

User Image topstockalerts Posted - 23 hours ago

$LYRA waking up now

User Image StockAuthority Posted - 23 hours ago

$LYRA this has a big gap like the others hmmm

User Image BlueCollarTrader1 Posted - 23 hours ago

$LYRA 🤔

User Image Gaphunters Posted - 23 hours ago

$LYRA be sure to add it on your watchlist! Stop missing out on the next big move!

User Image Smallsmall Posted - 23 hours ago

$AKAN next $LYRA

User Image Alaaaaaaa999999 Posted - 23 hours ago

$LYRA over 1 within weeks

User Image tm0801 Posted - 1 day ago

$LYRA they have one drug left before having to shut the company down and they can't even run a trial properly LMFAO

User Image tm0801 Posted - 1 day ago

$LYRA if there was even a hint of good news about the phase 2 trial they would be sharing it. it definitely failed

User Image Gregory_Roberts Posted - 1 day ago

$LYRA 20k shares opened this morning let's see what happens

User Image samjohnson2007 Posted - 1 day ago

$LYRA Breaking news: The clinical data was labled worngly during the statisitcal processing by CRO company, so they have hired a YALE univeristy biostatisitcs GROUP to re-validate the results https://ysph.yale.edu/c2s2/

User Image Zardiw Posted - 1 day ago

$LYRA Bounce? Chart from #DDAmanda - #1 Stock Screener : Find Winners Early Z

User Image tm0801 Posted - 1 day ago

$LYRA overreaction to what? Having one of their only 2 drugs fail and waiting for the other to fail as well? after that all they have is bankruptcy and closing the company down. they have nothing

User Image Jswole87 Posted - 1 day ago

$LYRA added more here

User Image Zardiw Posted - 1 day ago

$LYRA would make great material for a Short Squeeze.......just like $GWAV, $CRKN and $FFIE ..........just needs a spark.......lol Z

User Image LoveRetailFroth Posted - 1 day ago

$LYRA Atleast 4 to 5 X from here. Could run quick. Overreaction

User Image Chuckyboss1 Posted - 1 day ago

$LYRA this one’s going to move Wall Street bets needs to find this one

User Image dsmith13579 Posted - 1 day ago

$LYRA

User Image Swankyness1 Posted - 1 day ago

$CRKN $NCPL $VERB $GWAV $LYRA

User Image Swankyness1 Posted - 1 day ago

$CRKN move to $LYRA .. This is bottomed out and tons of money to be made !!

User Image RallyRaider Posted - 1 day ago

$LYRA should be next to run. They really went all out bringing it down here. they have cash and a dollar is still a dollar.

Analyst Ratings
HC Wainwright & Co. Neutral May 7, 24
Jefferies Hold May 7, 24
BTIG Neutral May 6, 24
HC Wainwright & Co. Buy May 1, 24
B of A Securities Buy Mar 25, 24
HC Wainwright & Co. Buy Mar 22, 24
HC Wainwright & Co. Buy Oct 2, 23
B of A Securities Buy Sep 12, 23
HC Wainwright & Co. Buy Aug 31, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Waksal Harlan Executive Chair Executive Chair Nov 10 Buy 2.9638 25,000 74,095 261,966 11/13/23
MERRIFIELD C ANN Director Director May 13 Buy 4.91 3,828 18,795 7,328 05/17/22
PERCEPTIVE ADVISORS LLC Director Director Apr 12 Buy 4.22 5,924,170 24,999,997 7,858,285 04/14/22
Waksal Harlan Executive Chair Executive Chair Apr 12 Buy 4.22 236,966 999,997 236,966 04/13/22